Ching-Wei Chang

6PUBLICATIONS
93CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Mineral processing/beneficiationTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Nov 03, 2023
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer.

Komal L Jhaveri, Meritxell Bellet, Nicholas C Turner

|Jun 01, 2023
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer.

Sarat Chandarlapaty, Maura N Dickler, Jose Alejandro Perez Fidalgo

|Jan 03, 2023
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.

Charles N Landen, Luciana Molinero, Habib Hamidi

|Sep 21, 2022
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.

Jackson Liang, Ellen Rei Ingalla, Xiaosai Yao

|May 18, 2022
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.

Geoffrey J Lindeman, Tharu M Fernando, Rebecca Bowen

|May 13, 2022
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer.

Kyung-Min Lee, Chang-Ching Lin, Alberto Servetto

Pageof 1

Frequent Collaborators

3 joint publications

Heather M Moore

2 joint publications

Ciara Metcalfe

2 joint publications

Mary R Gates

2 joint publications

Jose Alejandro Perez Fidalgo